JBIO as reported
- Net Income
- −$153M
Net Income · +67% year on year · trailing twelve months to Q2 2026
- EPS
- −$1.92
EPS · −90% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$153M | +67% | Q2 2026 |
| EPS | −$1.92 | −90% | Q2 2026 |
| ROE | −43% | n/a | Q2 2026 |
| ROA | −40% | n/a | Q2 2026 |
| Free Cash Flow | −$57M | n/a | Q4 2023 · 10 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Jade Biosciences, Inc. (JBIO) - Net IncomeNet IncomeJade Biosciences, Inc. (JBIO)